Boothbay Fund Management, LLC Celldex Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

$3.6 Billion
Q3 2024

A detailed history of Boothbay Fund Management, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 90,200 shares of CLDX stock, worth $2.03 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

90,200

Holding current value

$2.03 Million

% of portfolio

0.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $406,821 - $554,788	-11,697 Reduced 37.4%	19,576 $704,000
Q4 2022 Feb 14, 2023	SELL	$27.78 - $45.38 $162,374 - $265,246	-5,845 Reduced 15.75%	31,273 $1.39 Million
Q3 2022 Nov 14, 2022	SELL	$22.7 - $37.57 $566,296 - $937,258	-24,947 Reduced 40.19%	37,118 $1.04 Million
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $459,238 - $653,301	16,615 Added 36.56%	62,065 $2.11 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $679,382 - $1.07 Million	19,041 Added 72.1%	45,450 $1.76 Million
Q3 2021 Nov 15, 2021	SELL	$28.95 - $55.99 $750,644 - $1.45 Million	-25,929 Reduced 49.54%	26,409 $1.43 Million
Q2 2021 Aug 16, 2021	SELL	$20.71 - $35.37 $452,741 - $773,223	-21,861 Reduced 29.46%	52,338 $1.75 Million
Q1 2021 May 17, 2021	SELL	$16.19 - $29.91 $1.71 Million - $3.15 Million	-105,471 Reduced 58.7%	74,199 $1.53 Million
Q4 2020 Feb 12, 2021	SELL	$14.99 - $22.75 $96,640 - $146,669	-6,447 Reduced 3.46%	179,670 $3.15 Million
Q3 2020 Nov 16, 2020	SELL	$9.65 - $15.19 $219,238 - $345,101	-22,719 Reduced 10.88%	186,117 $2.76 Million
Q2 2020 Aug 14, 2020	BUY	$1.61 - $13.41 $336,225 - $2.8 Million	208,836 New	208,836 $2.72 Million

Others Institutions Holding CLDX

# of Institutions

197

Shares Held

66M

Call Options Held

1.68M

Put Options Held

980K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.05B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Account

Boothbay Fund Management, LLC Celldex Therapeutics, Inc. Transaction History